NEXT Medicine aims to investigate the clinical use of exomic data from whole exome sequencing (WES) in patients with clinical indications for colorectal cancer/polyposis (CRCP) through a randomized controlled trial of usual care versus the addition of exome analysis.
This project aims to evaluate the effectiveness of WES technology to identify clinically relevant CRCP gene mutations, cost and patient derived measures. This project also aims to determine which results will be returned to patients. Additionally, this project also investigates how to best incorporate genomic data into official medical records.
CLIA certified results will be returned to participants and the experiences of patients will be evaluated.